Figure 1.

R-Tf-D-LP4 Peptide-Mediated Inhibition of Steatotic Liver Pathology in an HFD-32 Mouse Model

(A) Schematic presentation of the course of steatosis development induced by an HFD-32 diet and peptide treatment initiation. (B–D) Livers from mice fed chow (normal diet [ND]), HFD-32, or HFD-32 and treated with R-Tf-D-LP4 (14 mg/kg) from weeks 6–8 by intravenous (i.v.) injection of 100 μL 0.8% DMSO in HBSS (control) or with R-Tf-D-LP4 in HBSS every 2 days. The final blood DMSO concentration was 0.07% in control and peptide-treated mice. Mice were then sacrificed, and livers were removed, photographed (B), and weighed (C). Results are means ± SEM (n = 10; **p ≤ 0.01, ***p ≤ 0.001). Representative liver sections were stained with H&E (D) or oil red O (E).